Enovis Corp (ENOV)vsEdwards Lifesciences Corp (EW)
ENOV
Enovis Corp
$19.28
+4.73%
HEALTHCARE · Cap: $1.07B
EW
Edwards Lifesciences Corp
$84.37
-2.77%
HEALTHCARE · Cap: $49.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 184% more annual revenue ($6.51B vs $2.30B). EW leads profitability with a 15.4% profit margin vs -48.0%. ENOV appears more attractively valued with a PEG of 1.90. EW earns a higher WallStSmart Score of 55/100 (C).
ENOV
Buy55
out of 100
Grade: C
EW
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+34.6%
Fair Value
$34.86
Current Price
$19.28
$15.58 discount
Margin of Safety
+68.9%
Fair Value
$254.99
Current Price
$84.37
$170.62 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Earnings expanding 153.1% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Strong operational efficiency at 29.8%
Areas to Watch
Expensive relative to growth rate
3.2% revenue growth
Smaller company, higher risk/reward
Operating margin of 4.2%
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 25.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : ENOV
The strongest argument for ENOV centers on Price/Book, EPS Growth.
Bull Case : EW
The strongest argument for EW centers on Debt/Equity, Altman Z-Score, Operating Margin. Profitability is solid with margins at 15.4% and operating margin at 29.8%. Revenue growth of 13.6% demonstrates continued momentum.
Bear Case : ENOV
The primary concerns for ENOV are PEG Ratio, Revenue Growth, Market Cap.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 51.6x leaves little room for execution misses.
Key Dynamics to Monitor
ENOV profiles as a turnaround stock while EW is a mature play — different risk/reward profiles.
ENOV carries more volatility with a beta of 1.43 — expect wider price swings.
EW is growing revenue faster at 13.6% — sustainability is the question.
EW generates stronger free cash flow (585M), providing more financial flexibility.
Bottom Line
ENOV scores higher overall (55/100 vs 55/100). EW offers better value entry with a 68.9% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Enovis Corp
HEALTHCARE · MEDICAL DEVICES · USA
Enovis Corporation is a global medical technology company. The company is headquartered in Wilmington, Delaware.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?